NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
Clinical Trials
7 trialsNCT06824701 2025-12-03
TARZAN
University of Utah
Phase 1 Recruiting
NCT05983965 2025-09-10
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Recruiting
NCT05934838 2025-08-15
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05618366 2025-04-08
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT04624113 2024-02-21
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
Phase 1 Terminated